Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding

Invasive Glioblastoma Cells Acquire Stemness and Increased Akt Activation

(2015) Jennifer R. Molina et al.   NEOPLASIA

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Is a Potent Inhibitor of ATM- and DNA-PKCs-Mediated DNA Damage Responses

(2015) Bipasha Mukherjee et al.   NEOPLASIA

GDC-0941 enhances the lysosomal compartment via TFEB and primes glioblastoma cells to lysosomal membrane permeabilization and cell death

(2012) Stefanie Enzenmüller et al.   CANCER LETTERS

Targeting the PI3K Pathway in the Brain--Efficacy of a PI3K Inhibitor Optimized to Cross the Blood-Brain Barrier

(2012) L. Salphati et al.   CLINICAL CANCER RESEARCH

Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511

(2012) Mark H. Norman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Autophagy and Akt promote survival in glioma

(2011) Qi-Wen Fan et al.   Autophagy

Genetic profile of astrocytic and oligodendroglial gliomas

(2011) Hiroko Ohgaki et al.   Brain Tumor Pathology

Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial

(2011) David A. Reardon et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting mTOR globally in cancer: Thinking beyond rapamycin

(2011) Boris Shor et al.   CELL CYCLE

Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

(2011) D. Koul et al.   CLINICAL CANCER RESEARCH

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

(2011) R. Mallon et al.   CLINICAL CANCER RESEARCH

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

(2011) H. Tanaka et al.   CLINICAL CANCER RESEARCH

Targeting the AKT Pathway in Glioblastoma

(2011) Kelli A. McDowell et al.   CURRENT PHARMACEUTICAL DESIGN

The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion

(2011) Sze Ki Luk et al.   EUROPEAN JOURNAL OF CANCER

Activity of novel quinoxaline-derived chalcones on in vitro glioma cell proliferation

(2011) Tânia R. Mielcke et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)

(2011) Gordon W. Rewcastle et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide

(2011) G. Prasad et al.   NEURO-ONCOLOGY

Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma

(2011) Kenneth L. Pitter et al.   PLoS One

Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr

(2011) Carlos A Fedrigo et al.   Radiation Oncology

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

(2010) K. Yu et al.   CANCER RESEARCH

Preclinical Evaluation of Radiation and Perifosine in a Genetically and Histologically Accurate Model of Brainstem Glioma

(2010) O. J. Becher et al.   CANCER RESEARCH

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

(2010) J. N. Sarkaria et al.   CLINICAL CANCER RESEARCH

Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma

(2010) Ho-Shin Gwak et al.   INTERNATIONAL JOURNAL OF CANCER

North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme

(2010) Jann N. Sarkaria et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma

(2010) D. Koul et al.   NEURO-ONCOLOGY

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells

(2010) Jun Sunayama et al.   NEURO-ONCOLOGY

mTOR signaling in glioblastoma: lessons learned from bench to bedside

(2010) D. Akhavan et al.   NEURO-ONCOLOGY

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

(2010) Darcy A. Krueger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma

(2010) Q.-W. Fan et al.   Science Signaling

Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells

(2010) Jun Sunayama et al.   STEM CELLS

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

(2009) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Expression of Mutant p53 Proteins Implicates a Lineage Relationship between Neural Stem Cells and Malignant Astrocytic Glioma in a Murine Model

(2009) Yuan Wang et al.   CANCER CELL

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

mTOR signaling at a glance

(2009) M. Laplante et al.   JOURNAL OF CELL SCIENCE

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

(2009) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

(2009) T.-J. Liu et al.   MOLECULAR CANCER THERAPEUTICS

The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair

(2009) M -A Westhoff et al.   ONCOGENE

p53 Regulation of the IGF-1/AKT/mTOR Pathways and the Endosomal Compartment

(2009) Z. Feng   Cold Spring Harbor Perspectives in Biology

PI3K Signaling in Glioma-Animal Models and Therapeutic Challenges

(2008) Christine K. Cheng et al.   BRAIN PATHOLOGY

Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability

(2008) Q. Xue et al.   CANCER RESEARCH

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

Phosphatidylinositol 3-Kinase Inhibition Broadly Sensitizes Glioblastoma Cells to Death Receptor- and Drug-Induced Apoptosis

(2008) D. Opel et al.   CANCER RESEARCH

p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling

(2008) Andrei V. Budanov et al.   CELL

Noninvasive Imaging of Apoptosis and Its Application in Cancer Therapeutics

(2008) J. M. Coppola et al.   CLINICAL CANCER RESEARCH

Radiographic and Histopathologic Observations After Combined EGFR Inhibition and Hypofractionated Stereotactic Radiosurgery in Patients With Recurrent Malignant Gliomas

(2008) Amanda L. Schwer et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

(2008) Paul D. Brown et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

(2008) Michael D. Prados et al.   JOURNAL OF CLINICAL ONCOLOGY

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

(2008) Teri N. Kreisl et al.   JOURNAL OF NEURO-ONCOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation

(2008) Hongwu Zheng et al.   NATURE

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

PTEN signaling in brain: neuropathology and tumorigenesis

(2008) R Endersby et al.   ONCOGENE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE

The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1

(2008) Y. Sancak et al.   SCIENCE